Comparing intraoperative radiotherapy (IORT) and hypofractionated stereotactic radiotherapy (HSRT) after brain metastasis surgery: impact on oncological outcome and radionecrosis - Scorecard - MDSpire
Advertisement
Comparing intraoperative radiotherapy (IORT) and hypofractionated stereotactic radiotherapy (HSRT) after brain metastasis surgery: impact on oncological outcome and radionecrosis
Clinical Scorecard: Evaluating Intraoperative Radiotherapy versus Hypofractionated Stereotactic Radiotherapy Following Brain Metastasis Surgery: Effects on Cancer Outcomes and Radionecrosis
At a Glance
Category
Detail
Condition
Brain metastases requiring surgical resection and adjuvant radiotherapy
Key Mechanisms
IORT delivers immediate intraoperative radiation to the resection cavity; HSRT delivers precise postoperative stereotactic radiotherapy with fractionation
Target Population
Patients undergoing resection of brain metastases with a minimum 5 mm distance from critical structures
Care Setting
Neurosurgical and radiation oncology multidisciplinary tumor board setting with postoperative follow-up
Key Highlights
IORT is administered intraoperatively with a median dose of 20 Gy to the cavity surface using spherical applicators.
HSRT is delivered postoperatively with 5 fractions of 6–7 Gy targeting the resection cavity plus a 3-mm margin.
One-year radionecrosis incidence was significantly lower with IORT (3.7%) compared to HSRT (21.8%).
Guideline-Based Recommendations
Diagnosis
Confirm malignancy intraoperatively via frozen section analysis before IORT.
Use MRI at three-month intervals post-treatment to monitor intracranial progression and radionecrosis.
Management
Select radiation modality based on multidisciplinary tumor board recommendations considering tumor location and patient factors.
Administer IORT intraoperatively to reduce treatment delays and target volume uncertainties.
Use HSRT postoperatively with dose fractionation tailored to resection status (R0 or R1).
Monitoring & Follow-up
Perform standardized contrast-enhanced MRI every three months post-treatment.
Assess for treatment-related toxicities including radionecrosis according to institutional protocols.
Risks
HSRT is associated with higher rates of radionecrosis compared to IORT.
Consider neurocognitive toxicity risks when selecting adjuvant radiotherapy modality.
Patient & Prescribing Data
129 patients with 137 treated brain metastasis cavities; median age 64 years; varied primary histologies including NSCLC and breast cancer.
IORT provides immediate radiation with a median applicator size of 2.0 cm and median dose of 20 Gy; HSRT initiated median 29 days post-surgery with median PTV of 34.7 cm³ and biologically effective doses comparable to IORT.
Clinical Best Practices
Ensure minimum 5 mm distance between resection cavity and critical structures before selecting IORT or HSRT.
Use intraoperative frozen section to confirm malignancy prior to IORT application.
Tailor HSRT dose fractionation based on resection margin status (5 × 6 Gy for R0, 5 × 7 Gy for R1).
Incorporate multidisciplinary tumor board input for individualized treatment planning.
Monitor patients closely with MRI every three months to detect recurrence and radionecrosis early.
by Maria Neu, Ehab Shiban, Philipp Krauss, Björn Sommer, Zoha Roushan, Susanne Gutser, Christoph J. Maurer, Tilman Janzen, Georg Stüben, Klaus-Henning Kahl
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from March 16 - 31.
